Hospitalizations due to severe injection-related infections (e.g., endocarditis) are increasing with the opioid crisis. Trauma related to these illnesses and other life events is often unrecognized and impacts patients’ ability to self-advocate. Stigma also impacts treatment options presented to patients. For example, patients with substance use disorder (SUD) and infections requiring prolonged IV antibiotics are often required to remain hospitalized for the entire antibiotic course without offering treatment alternatives. These patients often have significant life traumas, post-traumatic stress disorder (PTSD), and life-threatening infections plus prolonged hospitalizations contribute to further trauma. The University of Kentucky has an ongoing clinical trial evaluating home IV antibiotics in patients with severe infections and OUD on buprenorphine, while also assessing for trauma and PTSD. During the study, additional barriers emerged such as residential treatment facilities and carceral settings not providing patients access to OUD medications (MOUD), leading to severe withdrawal, increased risk of death and other complications. This practice violates the Americans with Disabilities Act (ADA) and other laws, something that physicians and patients generally do not realize. Addiction psychiatrists can spark change and educate other physicians about the ADA as an effective advocacy tool, advocate for patient-centered treatment of injection-related infections and increase screening and treatment of SUD/other psychiatric comorbidity in this vulnerable patient population. We will review the basics of the ADA relevant to physician advocacy and successful collaborations between physicians with addiction expertise, ADA lawyers and advocacy groups to help improve health outcomes for people with SUDS and comorbid psychiatric disorders.